Silexion Therapeutics Corp (SLXN)

$1.11 -0.01 (-0.89%)
Market Cap 3.50M
Revenue (ttm) 0.00
Net Income (ttm) -11.91M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.60
Volume 101,254
Avg Vol 48,838
Day's Range N/A - N/A
Shares Out 3.13M
Stochastic %K 3%
Beta 0.06
Analysts Strong Sell
Price Target $6.00

Company Profile

Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatmen...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 2 674 3430
Fax: 972 2 643 0982
Address:
The Goldyne Savad Inst. of Gene Therapy, Hadassah Hebrew Univ Medical Ctr, Jerusalem, Israel
Taajom
Taajom Apr. 9 at 7:24 PM
$SLXN https://truthsandnews.com/finance/why-is-slxn-stock-trending-today-april-2026-forecast-news-analysis
0 · Reply
captainblacktop
captainblacktop Apr. 9 at 2:33 PM
$SLXN dang 70,000 on the bid
0 · Reply
ZacksResearch
ZacksResearch Apr. 8 at 1:57 PM
$SLXN down 43% in 3 months — bargain buy or falling knife? ⚠️ Trading at a 12-month trailing P/B of 1.35 vs. industry average of 3.49 📉 while loss estimates for 2026 have narrowed over the past 30 days — early signs sentiment could be stabilizing. See what Wall Street analysts recommend 👉 https://www.zacks.com/stock/research/SLXN/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-37688&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_37688
0 · Reply
Kakahi69
Kakahi69 Mar. 30 at 10:01 PM
$SLXN gaining momentum?
1 · Reply
2pumps1dump
2pumps1dump Mar. 25 at 10:31 PM
$SLXN bullish now that they can’t dilute the shit out of it. Need an exit asap. Increase equity incentive 😂
0 · Reply
WallStWireAds
WallStWireAds Mar. 25 at 1:50 PM
$SLXN Silexion Granted Approval to Launch Human Trials That Could Redefine the Future of Cancer Treatment https://www.benzinga.com/content/51430751/silexion-granted-approval-to-launch-human-trials-that-could-redefine-the-future-of-cancer-treatment
0 · Reply
captainblacktop
captainblacktop Mar. 24 at 4:07 PM
$SLXN Uno reverse it!
0 · Reply
WallStWireAds
WallStWireAds Mar. 24 at 1:48 PM
$SLXN https://caplynx.io/HQ3B07I
0 · Reply
StockElementCorporation
StockElementCorporation Mar. 24 at 12:50 PM
Premarket movers 📈 Upside: $NTGR +12% — FCC router import ban tailwind $JEF +7.9% — takeover interest from SMFG $SLXN +7.8% — Phase 2/3 pancreatic trial approved $BCRX +6.1% — momentum $SFD +6.0% — earnings; dividend hike LI +3.7% — $1B buyback JHG +2.8% — raised merger offer AAOI +2.3% — hyperscaler order Downside: OCGN -15% — Phase 2 data CNXC -11% — earnings ARES -4.8% — withdrawal limits
0 · Reply
WallStWireAds
WallStWireAds Mar. 24 at 12:39 PM
$SLXN https://caplynx.io/5028fjH
0 · Reply
Latest News on SLXN
Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Mar 24, 2026, 9:46 AM EDT - 16 days ago

Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer

Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 17, 2026, 5:01 PM EDT - 22 days ago

Silexion Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer

Dec 16, 2025, 8:40 AM EST - 4 months ago

Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Nov 26, 2025, 7:30 AM EST - 4 months ago

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer

Nov 25, 2025, 9:15 AM EST - 4 months ago

Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer

Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 12, 2025, 9:00 AM EST - 5 months ago

Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

Sep 30, 2025, 8:40 AM EDT - 6 months ago

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements

Sep 25, 2025, 8:45 AM EDT - 7 months ago

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements

Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data

Sep 11, 2025, 1:26 PM EDT - 7 months ago

Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

Sep 11, 2025, 9:17 AM EDT - 7 months ago

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

Sep 11, 2025, 7:00 AM EDT - 7 months ago

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204's Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204

Sep 4, 2025, 9:25 AM EDT - 7 months ago

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Sep 2, 2025, 8:45 AM EDT - 7 months ago

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 12, 2025, 8:00 AM EDT - 8 months ago

Silexion Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

Jul 31, 2025, 8:00 PM EDT - 8 months ago

Silexion Therapeutics Announces Exercise of Warrants for $1.8 Million Gross Proceeds

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

Jul 31, 2025, 9:55 AM EDT - 9 months ago

Silexion Therapeutics Announces New Preclinical Data Showing Up to 97% Inhibition of Cancer Cell Growth, Including New Evidence Against New Previously Untested KRAS Mutation

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

Jul 16, 2025, 8:44 AM EDT - 9 months ago

Silexion Therapeutics Announces 1-for-15 Reverse Share Split

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

Jul 9, 2025, 8:30 AM EDT - 9 months ago

Silexion Therapeutics Announces Positive Results in Preclinical Study Demonstrating Significant SIL204 Efficacy in Human Lung Cancer Cell Lines

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

May 22, 2025, 3:46 PM EDT - 11 months ago

PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

May 21, 2025, 8:45 AM EDT - 11 months ago

Silexion Therapeutics Completes Key Preclinical Studies Exploring SIL204's Potential Impact on Colorectal and Lung Cancer

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 13, 2025, 4:45 PM EDT - 11 months ago

Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Apr 23, 2025, 9:20 AM EDT - 1 year ago

Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Mar 28, 2025, 8:30 AM EDT - 1 year ago

Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Mar 21, 2025, 8:30 AM EDT - 1 year ago

Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Mar 18, 2025, 4:29 PM EDT - 1 year ago

Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Mar 17, 2025, 8:15 AM EDT - 1 year ago

PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment

Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer

Mar 5, 2025, 12:05 PM EST - 1 year ago

Silexion Therapeutics' Preclinical Cancer Candidate Shows Tumor Reduction For Pancreatic Cancer

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

Mar 5, 2025, 8:30 AM EST - 1 year ago

Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Mar 3, 2025, 8:30 AM EST - 1 year ago

PESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be Transformational

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Feb 25, 2025, 8:30 AM EST - 1 year ago

Silexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Jan 29, 2025, 5:30 PM EST - 1 year ago

Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Jan 29, 2025, 9:59 AM EST - 1 year ago

PESG Report: Silexion Therapeutics' Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Jan 28, 2025, 8:29 AM EST - 1 year ago

Silexion Therapeutics Reports Strong Tumor Growth Reduction from Systemic Administration of SIL-204 in Preclinical Pancreatic Cancer Models

Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies

Jan 16, 2025, 12:08 PM EST - 1 year ago

Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies

PESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Jan 16, 2025, 11:04 AM EST - 1 year ago

PESG Market Update: Silexion Therapeutics' SIL-204 Shows Groundbreaking Synergy in Preclinical Data, Boosting Hope for KRAS-Driven Cancer Treatments

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Jan 16, 2025, 8:51 AM EST - 1 year ago

Southwest Airlines, Silexion Therapeutics And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

LUV

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Jan 15, 2025, 8:00 PM EST - 1 year ago

Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Jan 15, 2025, 4:01 PM EST - 1 year ago

Silexion Therapeutics Announces Additional Promising Preclinical Data for SIL-204, Demonstrating Impressive Synergy with First-Line Pancreatic Cancer Chemotherapies

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

Jan 13, 2025, 7:50 AM EST - 1 year ago

Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

Dec 17, 2024, 9:36 AM EST - 1 year ago

PESG Releases Market Update: Silexion Therapeutics Advances KRAS-Targeting Therapies with New Collaboration As Industry Demand for Precision Oncology Solutions Rises

AMGN

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Nov 22, 2024, 4:30 PM EST - 1 year ago

Silexion Therapeutics Announces 1-for-9 Reverse Share Split

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

Nov 20, 2024, 8:30 AM EST - 1 year ago

Silexion Therapeutics to Present at the Noble Capital Markets 20th Annual Emerging Growth Equity Conference

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Oct 1, 2024, 6:45 AM EDT - 1 year ago

Silexion Therapeutics Reports Breakthroughs From SIL-204 Preclinical Studies

Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise

Sep 24, 2024, 9:25 AM EDT - 1 year ago

Silexion Therapeutics Stock Trades Higher, Trial Data For Pancreatic Cancer Patients Shows Promise

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

Sep 24, 2024, 7:30 AM EDT - 1 year ago

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Sep 9, 2024, 7:32 AM EDT - 1 year ago

PESG Releases Report on Silexion Therapeutics: Pioneering RNAi Technology in the Fight Against KRAS-Driven Cancers

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Silexion Therapeutics to Present at the H.C. Wainright 26th Annual Global Investment Conference

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

Aug 15, 2024, 4:05 PM EDT - 1 year ago

Silexion Therapeutics Ltd. and Moringa Acquisition Corp Announce Closing of their Business Combination

Taajom
Taajom Apr. 9 at 7:24 PM
$SLXN https://truthsandnews.com/finance/why-is-slxn-stock-trending-today-april-2026-forecast-news-analysis
0 · Reply
captainblacktop
captainblacktop Apr. 9 at 2:33 PM
$SLXN dang 70,000 on the bid
0 · Reply
ZacksResearch
ZacksResearch Apr. 8 at 1:57 PM
$SLXN down 43% in 3 months — bargain buy or falling knife? ⚠️ Trading at a 12-month trailing P/B of 1.35 vs. industry average of 3.49 📉 while loss estimates for 2026 have narrowed over the past 30 days — early signs sentiment could be stabilizing. See what Wall Street analysts recommend 👉 https://www.zacks.com/stock/research/SLXN/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-oc-37688&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_OC_37688
0 · Reply
Kakahi69
Kakahi69 Mar. 30 at 10:01 PM
$SLXN gaining momentum?
1 · Reply
2pumps1dump
2pumps1dump Mar. 25 at 10:31 PM
$SLXN bullish now that they can’t dilute the shit out of it. Need an exit asap. Increase equity incentive 😂
0 · Reply
WallStWireAds
WallStWireAds Mar. 25 at 1:50 PM
$SLXN Silexion Granted Approval to Launch Human Trials That Could Redefine the Future of Cancer Treatment https://www.benzinga.com/content/51430751/silexion-granted-approval-to-launch-human-trials-that-could-redefine-the-future-of-cancer-treatment
0 · Reply
captainblacktop
captainblacktop Mar. 24 at 4:07 PM
$SLXN Uno reverse it!
0 · Reply
WallStWireAds
WallStWireAds Mar. 24 at 1:48 PM
$SLXN https://caplynx.io/HQ3B07I
0 · Reply
StockElementCorporation
StockElementCorporation Mar. 24 at 12:50 PM
Premarket movers 📈 Upside: $NTGR +12% — FCC router import ban tailwind $JEF +7.9% — takeover interest from SMFG $SLXN +7.8% — Phase 2/3 pancreatic trial approved $BCRX +6.1% — momentum $SFD +6.0% — earnings; dividend hike LI +3.7% — $1B buyback JHG +2.8% — raised merger offer AAOI +2.3% — hyperscaler order Downside: OCGN -15% — Phase 2 data CNXC -11% — earnings ARES -4.8% — withdrawal limits
0 · Reply
WallStWireAds
WallStWireAds Mar. 24 at 12:39 PM
$SLXN https://caplynx.io/5028fjH
0 · Reply
2pumps1dump
2pumps1dump Mar. 24 at 12:38 PM
$SLXN run it 🏃🏽‍♂️
0 · Reply
Stock_Catcher
Stock_Catcher Mar. 24 at 12:37 PM
$SLXN Silexion Therapeutics Receives Approval from Israeli Ministry of Health to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
0 · Reply
topstockalerts
topstockalerts Mar. 20 at 8:47 PM
After Hours Top Gainers $RECT $RPGL $SGLY $SLXN $DFSC
0 · Reply
captainblacktop
captainblacktop Mar. 17 at 10:24 PM
$SLXN if anyone from SLXN reads this board..STOP calling shareholders every 4 hours to vote.. we'll vote once you get this thing moving past $9
1 · Reply
captainblacktop
captainblacktop Mar. 17 at 10:20 PM
$SLXN less than $10K volume day..and no movement on good news.. smh... it's like watching dried paint
0 · Reply
WallStWireAds
WallStWireAds Mar. 17 at 9:04 PM
$SLXN https://caplynx.io/4zGMR09
0 · Reply
LHProxy
LHProxy Mar. 16 at 7:42 PM
$SLXN Extraordinary Shareholder Meeting has been adjourned to 3/23 due to insufficient shareholder participation. If you hold shares, please call 888‑742‑1305 to submit your vote ASAP—every share counts.
1 · Reply
BillionerOfKing
BillionerOfKing Mar. 10 at 11:29 PM
$SLXN Current Stock Price: $1.88
0 · Reply
captainblacktop
captainblacktop Mar. 10 at 1:28 PM
$SLXN something's brewing
1 · Reply
LHProxy
LHProxy Mar. 5 at 3:35 PM
$SLXN
0 · Reply
LHProxy
LHProxy Mar. 5 at 3:35 PM
$SLXN *Extraordinary General Meeting* on March 16th - Call 888.742.1305 with any questions and to vote your shares! https://www.globenewswire.com/news-release/2026/03/05/3250105/0/en/Silexion-Therapeutics-Urges-Shareholders-to-Vote-Ahead-of-March-16-Extraordinary-General-Meeting.html
0 · Reply
WallStWireAds
WallStWireAds Mar. 5 at 1:03 PM
$SLXN https://caplynx.io/HIJ6FJV
0 · Reply